NASDAQ:MREO Mereo BioPharma Group Q2 2026 Earnings Report $0.33 +0.01 (+4.46%) As of 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mereo BioPharma Group EPS ResultsActual EPSN/AConsensus EPS -$0.01Beat/MissN/AOne Year Ago EPSN/AMereo BioPharma Group Revenue ResultsActual RevenueN/AExpected Revenue$3.50 millionBeat/MissN/AYoY Revenue GrowthN/AMereo BioPharma Group Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time2:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Mereo BioPharma Group Earnings HeadlinesMereo BioPharma Group Corporate Event Calendar | NASDAQ:MREO1 hour ago | benzinga.comShort Interest in Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Decreases By 34.5%July 4, 2026 | americanbankingnews.comThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline because the information inside is too sensitive to leave up indefinitely. Inside the remaining copies is the executive order Trump can sign tomorrow, the same legal authority FDR used in 1934 to move billions in wealth overnight, and exactly how to position before it happens.July 15 at 1:00 AM | American Alternative (Ad)Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Consensus Recommendation of "Hold" by BrokeragesJuly 4, 2026 | americanbankingnews.com4basebio Announces Appointment of Chief Financial Officer and Board ChangesMay 14, 2026 | globenewswire.comMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | globenewswire.comSee More Mereo BioPharma Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email. Email Address About Mereo BioPharma GroupMereo BioPharma Group (NASDAQ:MREO) plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate. Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases. Additional clinical programs target oncology and immunology indications, leveraging both internally developed molecules and partnerships with third-party biotech and pharmaceutical companies. The company conducts multi‐center trials in Europe and North America, collaborating with academic institutions and contract research organizations to advance its clinical objectives. Established in 2013 and headquartered in London, Mereo BioPharma has built a team with expertise in clinical development, regulatory affairs and corporate strategy to support its focused portfolio. The company’s business strategy emphasizes strategic alliances, out-licensing opportunities and selective acquisitions to enhance shareholder value and ensure sustained progress across its pipeline. Mereo is listed on the NASDAQ under the ticker symbol MREO and maintains operations in the United Kingdom, United States and Europe.View Mereo BioPharma Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-MergerMarriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Upcoming Earnings GE Aerospace (7/16/2026)Taiwan Semiconductor Manufacturing (7/16/2026)Netflix (7/16/2026)Prologis (7/16/2026)State Street (7/16/2026)U.S. Bancorp (7/16/2026)Abbott Laboratories (7/16/2026)Intuitive Surgical (7/16/2026)UnitedHealth Group (7/16/2026)Fifth Third Bancorp (7/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
